1. Home
  2. AIN vs AUPH Comparison

AIN vs AUPH Comparison

Compare AIN & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Albany International Corporation

AIN

Albany International Corporation

HOLD

Current Price

$52.94

Market Cap

1.7B

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$16.01

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIN
AUPH
Founded
1895
1993
Country
United States
Canada
Employees
N/A
N/A
Industry
Textiles
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.9B
IPO Year
1994
2014

Fundamental Metrics

Financial Performance
Metric
AIN
AUPH
Price
$52.94
$16.01
Analyst Decision
Hold
Buy
Analyst Count
4
4
Target Price
$60.25
$17.25
AVG Volume (30 Days)
242.7K
1.1M
Earning Date
04-29-2026
05-11-2026
Dividend Yield
2.14%
N/A
EPS Growth
N/A
5075.00
EPS
N/A
2.07
Revenue
$1,054,132,000.00
$283,055,000.00
Revenue This Year
$1.20
$16.53
Revenue Next Year
N/A
$16.24
P/E Ratio
N/A
$7.54
Revenue Growth
7.29
20.38
52 Week Low
$41.15
$6.83
52 Week High
$73.00
$16.54

Technical Indicators

Market Signals
Indicator
AIN
AUPH
Relative Strength Index (RSI) 47.38 66.55
Support Level $51.74 $14.56
Resistance Level $53.88 $16.28
Average True Range (ATR) 1.73 0.55
MACD 0.20 0.20
Stochastic Oscillator 66.19 87.43

Price Performance

Historical Comparison
AIN
AUPH

About AIN Albany International Corporation

Albany International Corp is principally engaged in processing textiles and materials. The company consists of two business segments, the machine clothing segment, which produces and provides custom-designed fabrics and belts for the production in the paper, nonwovens, and other process industries; and the Albany engineered composites segment, which offers engineered composite parts for the aerospace and defensive industries. The machine clothing segment contributes to the majority of the company's total revenue. The company has an operation and generates revenue from the United States, Switzerland, Brazil, China, Mexico, France, and other areas.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: